48,740 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Castleark Management LLC

Castleark Management LLC acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the first quarter, HoldingsChannel.com reports. The fund acquired 48,740 shares of the specialty pharmaceutical company’s stock, valued at approximately $9,214,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. ABS Direct Equity Fund LLC purchased a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $187,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $8,186,000. Public Employees Retirement System of Ohio boosted its stake in shares of Jazz Pharmaceuticals by 19.0% in the first quarter. Public Employees Retirement System of Ohio now owns 48,490 shares of the specialty pharmaceutical company’s stock valued at $9,167,000 after buying an additional 7,744 shares in the last quarter. Compound Planning Inc. boosted its stake in shares of Jazz Pharmaceuticals by 14.6% in the first quarter. Compound Planning Inc. now owns 2,110 shares of the specialty pharmaceutical company’s stock valued at $399,000 after buying an additional 269 shares in the last quarter. Finally, Systematic Financial Management LP grew its holdings in Jazz Pharmaceuticals by 2.6% during the first quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock worth $76,965,000 after acquiring an additional 10,237 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the transaction, the director directly owned 366,682 shares in the company, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Douglas Smith sold 1,157 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the transaction, the director owned 9,680 shares of the company’s stock, valued at $2,231,724. This trade represents a 10.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $253.87 on Monday. The stock has a fifty day moving average price of $237.37 and a 200 day moving average price of $203.44. The stock has a market cap of $15.95 billion, a PE ratio of -12,687.16, a P/E/G ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $256.75. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on JAZZ shares. Wells Fargo & Company increased their price objective on Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Raymond James Financial restated an “outperform” rating and set a $239.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $188.00 to $307.00 in a report on Tuesday, May 19th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, June 9th. Finally, Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $259.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.